Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
225Ac-PSMA-R2 · 1 trial · 1 indication
To determine the Recommended Dose for Expansion (RDE) and corresponding regimen for 225Ac-PSMA-R2 monotherapy in PSMA-positive in: * Group-1 (mCRPC): Participants previously treated with 177Lu-labelled PSMA-targeted RLT (post-177Lu). * Group-2 (mCRPC): Participants not treated previously with 177Lu-labelled PSMA-targeted RLT (pre-177Lu). * Group-3 (mHSPC): Participants not treated previously with 177Lu-labelled PSMA-targeted RLT (pre-177Lu).
The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.
Frequency of dose interruptions, reductions, discontinuations, and dose intensity by group.
Overall Response Rate (ORR) is defined as the proportion of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR) in soft tissue according to Prostate Cancer Working Group 3 (PCWG3) -modified RECIST v1.1 in absence of bone progression (as per PCWG3).
| Arm | Type | Description |
|---|---|---|
| Group-1 (mCRPC/ post-177Lu) | EXPERIMENTAL | 1. Dose Escalation: All eligible participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) who have received anti-cancer treatment (post-Androgen Receptor Pathway Inhibitors (ARPI), post-taxane based chemotherapy and heavily pre-treated and having already received prior 177Lu-labelled Prostate Specific Membrane Antigen (PSMA)-targeting Radioligand Therapy (RLT) will receive the starting dose of 7 Megabecquerel (MBq) of 225Ac-PSMA-R2 to determine the Maximum Tolerated Dose/Recommended Dose for Expansion (MTD/RDE) of Group 1. 2. Dose Expansion: Once RDE is determined for Group 1, participants who have previously received 177Lu-PSMA-RLT will be enrolled in Group 1 dose expansion. |
| Group-2 (mCRPC/ pre-177Lu) | EXPERIMENTAL | 1. Dose Escalation: All eligible participants with mCRPC who have received anti-cancer treatment (post-Androgen Receptor Pathway Inhibitors (ARPI), prior taxane-based chemotherapy is not required, but have never been treated with 177Lu-labelled PSMA-targeted RLT (177Lu-labelled PSMA-targeted RLT treatment naïve) will receive the starting dose of 7 Megabecquerel (MBq) of 225Ac-PSMA-R2 to determine the Maximum Tolerated Dose/Recommended Dose for Expansion (MTD/RDE) of Group 2. 2. Dose Expansion: Once RDE is determined for Group 2, participants naïve to 177Lu-labelled PSMA-targeted Radioligand Therapy (RLT) will be enrolled in Group 2 dose expansion. |
| Group 3 (mHSPC/ pre-177Lu) | EXPERIMENTAL | 1. Dose Escalation: All eligible participants with mHSPC (177Lu-labelled PSMA-targeted RLT treatment naïve), who are treatment naive or minimally treated with a) luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or bilateral orchiectomy with or without first generation antiandrogen (e.g. bicalutamide, flutamide) b) CYP17 inhibitor or ARDT exposure. Patient in this group will start treatment with 225Ac-PSMA-R2 after group 1 and group 2 patients. 2. Dose Expansion: Once RDE is determined for Group 3, participants will be enrolled in Group 3 dose expansion. |
| Name | Type | Description |
|---|---|---|
| 225Ac-PSMA-R2 | DRUG | PSMA-R2 is a ligand coupled with 225Ac an alpha emitting radionuclide |
| 68Ga-PSMA-R2 | RADIATION | Kit for radiopharmaceutical preparation |
| 68Ga-PSMA-11 | RADIATION | Kit for radiopharmaceutical preparation |
Key Inclusion Criteria: * Evidence of PSMA-positive disease by 68Ga-PSMA-11 PET/CT and eligible as determined by central reading * Documented progressive mCRPC or mHSPC * Adequate organ function * Prior orchiectomy or ongoing ADT and should have received prior 177Lu-PSMA-RLT (Group1 dose escalation...
Top 20 of 55 competitors
225Ac-PSMA-R2 is an investigational small molecule radiopharmaceutical being developed by Novartis AG for prostate cancer. It is designed to deliver the alpha-emitting radioisotope actinium-225 to prostate cancer cells. It is currently in Phase 1 clinical development and has not been approved by any regulatory agency.
225Ac-PSMA-R2 is being studied for the treatment of PSMA-positive prostate cancer. The ongoing Phase I/II trial enrolls adult male patients with PSMA-positive prostate cancer, including those who have or have not received prior 177Lu-PSMA radioligand therapy. It is an investigational therapy and is not yet approved for any indication.
225Ac-PSMA-R2 targets prostate-specific membrane antigen (PSMA), a protein expressed on the surface of prostate cancer cells. The drug uses a small molecule binder to PSMA to deliver actinium-225, an alpha-emitting radioisotope, directly to PSMA-positive tumor cells.
225Ac-PSMA-R2 is being developed by Novartis AG, which trades on the New York Stock Exchange under the ticker symbol NVS. Novartis is the sponsor of the ongoing Phase I/II clinical trial for this radiopharmaceutical.
225Ac-PSMA-R2 is in Phase 1 clinical development. The only registered trial is a Phase I/II study that is currently active but not recruiting. The drug has not been approved by the FDA or any other regulatory authority and remains investigational.
225Ac-PSMA-R2 is being evaluated in one clinical trial, NCT05983198, titled "Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT." The trial is active but not recruiting, with an estimated enrollment of 33 participants across the United States, Australia, Canada, and France.